CA-MOVIUS
Movius , the leading global provider of mobile unified communication software, is now enabling enterprises to securely and compliantly communicate with clients on their preferred mobile messaging channel. Today, the company announced the integration of WhatsApp support from within Movius MultiLine, their secure mobile communication service that can be deployed over any smartphone device on any global carrier. The integration will help unify and capture all business voice and messaging channels through a single integrated user experience, while enabling firms to effortlessly meet regulatory and surveillance needs.
An open Beta for this integration is available now and general availability is expected in the fourth quarter, 2020. As users continue to work remotely, they will find the expanded enterprise service provides unmatched productivity anywhere – and compliance everywhere – especially as companies accelerate their emerging Bring Your Own Device (BYOD) strategies and implementations.
WhatsApp users will experience a single, global solution that auto-archives in accordance with regulation and surveillance protocols – improving customer engagement for users, while simultaneously putting to rest any compliance gap concerns for the enterprise. This expansion of the MultiLine service, which integrates messaging, voice and compliance into enterprise workflows, lets Movius users leverage existing communications preferences and increase productivity – no matter where they are.
As digital transformation continues to accelerate, customers are quickly adapting to new mobile channels and expect the solutions that support them to do the same. With the rising popularity of services like WhatsApp – with two billion users worldwide – firms run the risk of unsanctioned use from their employees as they interact with clients. Or, by sanctioning a “no WhatsApp policy,” they risk alienating customers that prefer WhatsApp as their way to connect. Not only can data become unsafe when WhatsApp is used on personal devices, but the encryption makes it difficult to monitor and supervise activity, a necessary record-keeping oversight for regulated industries.
“We see this as an opportunity for enterprises to effectively leverage the business side of WhatsApp, endeavoring to bring that form of communication in the realm of compliance, supervision and client affinity, rather than banning and restricting the use of a popular way to connect,” said Movius Chief Product and Technology Officer, Amit Modi. “This is how enterprises are communicating and what their clients are demanding, and we stand by our mission to provide enterprises with compliant, reliable mobile communications that enable employees to communicate with clients whether they are sitting desk side or working remotely.”
With this integration, customers can engage with voice, text and WhatsApp all through a single interface, while allowing firms to have complete ownership and visibility into business conversations. Bringing these forms of communication into one place also allows for complete separation of business and personal correspondence among BYOD users, allowing firms to ensure their business data is protected and employees’ personal data remains private and untouched.
To learn more and request Beta access, click here: www.moviuscorp.com/whatsapp . Interested parties can also join webinars on the WhatsApp integration starting October 6; learn more about those here: https://moviuscorp.com/product-webinar-introducing-movius-whatsapp-messaging-connector/ .
About Movius
Movius is the leading global provider of mobile unified communications for the new world of work, offering productivity anywhere and compliance everywhere. Movius software and services integrate messaging, voice and compliance into enterprise workflows which helps organizations like JP Morgan Chase & Co, UBS, Jefferies, BCG Partners and Cantor Fitzgerald deliver better engagement for their clients. Enterprises around the world use the company’s all-in-one mobility platform to connect with their customers in more convenient, cost-effective and compliant ways.
The platform offers an easy way to extend and integrate voice, text, and messaging services into other systems, like CRM or collaboration tools. Movius recently released several new product capabilities, including WhatsApp support and integration with Salesforce CRM. These capabilities deliver additional customer value and can elevate the role MultiLine plays in customer organizations.
Headquartered in Atlanta, Movius has additional locations in Silicon Valley, Calif., and Bangalore, India. Movius works with leading global partners like T-Mobile, BlackBerry, BT Global, Telstra, and Telefónica. For more information on Movius, visit https://www.moviuscorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005730/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom